Kosuke Harada
Overview
Explore the profile of Kosuke Harada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naraoka H, Iguchi T, Harada K, Usui T, Suwa Y, Ando M, et al.
Drug Metab Pharmacokinet
. 2025 Jan;
60:101034.
PMID: 39847981
Regulatory authorities and pharmaceutical companies in Europe and the United States have paid attention to microphysiological systems (MPS), and various consortia and academic societies have been established. They are actively...
2.
Yasuda S, Bando K, Henry M, Libertini S, Watanabe T, Bando H, et al.
Stem Cells Transl Med
. 2024 Aug;
13(10):1001-1014.
PMID: 39120125
The presence of residual undifferentiated pluripotent stem cells (PSCs) in PSC-derived cell therapy products (CTPs) is a major safety issue for their clinical application, due to the potential risk of...
3.
Harada K, Wenlong W, Shinozawa T
Sci Rep
. 2024 Jun;
14(1):14109.
PMID: 38898080
Developing a reliable method to predict thrombocytopenia is imperative in drug discovery. Here, we establish an assay using a microphysiological system (MPS) to recapitulate the in-vivo mechanisms of platelet aggregation...
4.
Harada K, Furukawa H, Kohara H, Nishimura K, Komori H, Okai Y, et al.
Toxicol In Vitro
. 2023 Feb;
89:105569.
PMID: 36801361
In this study, we investigated thrombocytopenia caused by cholesterol-conjugated antisense oligonucleotides (Chol-ASO). First, we evaluated platelet activation induced by Chol-ASO in mice by flow cytometry after administration of platelet-rich plasma...
5.
Harada K, Kohara H, Yukawa T, Matsumiya K, Shinozawa T
Toxicol In Vitro
. 2021 Apr;
74:105159.
PMID: 33823239
Here, we established a high-throughput in vitro assay system to predict reactive metabolite (RM) formation. First, we performed the glutathione (GSH) consumption assay to monitor GSH levels as an index...
6.
Okai Y, Matsune K, Yamanaka K, Matsui T, Kaushik E, Harada K, et al.
J Pharmacol Toxicol Methods
. 2020 Jul;
105:106893.
PMID: 32619502
Introduction: Drug-induced inotropic change is a risk factor in drug development; thus, de-risking is desired in the early stages of drug development. Unlike proarrhythmic risk assessment using human induced pluripotent...
7.
Kohara H, Bajaj P, Yamanaka K, Miyawaki A, Harada K, Miyamoto K, et al.
Toxicol Sci
. 2019 Nov;
173(2):347-361.
PMID: 31722436
Cholestasis resulting from hepatic bile acid efflux transporter inhibition may contribute to drug-induced liver injury (DILI). This condition is a common safety-related reason for drug attrition and withdrawal. To screen...
8.
Putra A, Chung K, Flinn B, Kuykendall T, Zheng C, Harada K, et al.
J Prosthet Dent
. 2017 Feb;
118(3):422-429.
PMID: 28238306
Statement Of Problem: Studies of the light transmission of translucent zirconias after hydrothermal treatment are limited. Purpose: The purpose of this in vitro study was to evaluate the effect of...
9.
Harada K, Raigrodski A, Chung K, Flinn B, Dogan S, Mancl L
J Prosthet Dent
. 2016 Mar;
116(2):257-63.
PMID: 26994676
Statement Of Problem: Studies comparing the translucency of zirconias and lithium disilicates are limited. Purpose: The purpose of this in vitro study was to measure the translucency of recently developed...
10.
Harada K, Shinya A, Gomi H, Hatano Y, Shinya A, Raigrodski A
J Prosthet Dent
. 2015 Nov;
115(2):215-23.
PMID: 26548887
Statement Of Problem: Low temperature degradation (LTD) of yttria-stabilized tetragonal zirconia polycrystals (Y-TZP) is of concern. Purpose: The purpose of this in vitro study was to assess the effect of...